The U.S. Meals and Drug Administration (FDA) on Thursday accredited a brand new possibility for sufferers to self-inject Argenx SE’s ARGX Vyvgart Hytrulo with a prefilled syringe (efgartigimod alfa and hyaluronidase-qvfc) for grownup sufferers with generalized myasthenia gravis (gMG) who’re anti-acetylcholine receptor (AChR) antibody constructive and grownup sufferers with persistent inflammatory demyelinating polyneuropathy (CIDP).
Vyvgart Hytrulo prefilled syringe for self-injection is accredited as a 20-to-30-second subcutaneous injection administered by a affected person, caregiver, or healthcare skilled.
The one-dose prefilled subcutaneous injection was developed as a part of argenx’s unique partnership with Halozyme Therapeutics Inc’s HALO Enhanze drug supply know-how, enabling speedy, high-volume biologics supply.
Additionally Learn: Argenx’s Flagship Drug Vyvgart Reveals Sustained Illness Management In Uncommon Neuromuscular Illness Sufferers
The approval of the Vyvgart Hytrulo prefilled syringe for self-injection is supported by information from research evaluating its bioequivalence to Vyvgart Hytrulo in a vial.
As well as, human components validation research demonstrated that members with gMG or CIDP, or their caregivers, safely and efficiently ready and administered Vyvgart Hytrulo with the prefilled syringe. Earlier FDA approval of Vyvgart Hytrulo for sufferers with gMG and CIDP was based mostly on the worldwide Part 3 ADAPT, ADAPT-SC, and ADHERE trials.
William Blair writes the self-administration possibility shall be a powerful progress driver for the Vyvgart franchise in each MG and CIDP, enabling sufferers to have a excessive diploma of flexibility and increasing the overall addressable market.
The analyst writes that some sufferers might improve the frequency of dosing, given the comfort of self-administration, to realize extra steady symptom reduction, as mirrored by the every-2-to-3-weeks dosing evaluated within the ADAPT-NXT trial. This might be one other progress driver for the prefilled syringe.
“Whereas different choices for CIDP and MG are in improvement, together with trials for prefilled syringe formulations, we imagine Argenx’s first-to-market benefit provides to its giant aggressive moat in each indications,” analyst Myles Minter wrote.
William Blair maintains Argenx with an Outperform ranking.
Worth Motion: ARGX inventory closed larger by 6.36% to $580.97on Friday.
Learn Subsequent:
Market Information and Knowledge delivered to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
